About Lucence | Lucence

Earlier Detection.
Better Health.

Our Vision

A world where cancer is overcome by early detection and informed treatment.

Our Mission

Accelerating towards a world where people live longer and healthier lives,
enabled through non-invasive technology achieving earlier detection of cancer and other aging diseases.

About Us

Earlier Detection.
Better Health.

What if health conditions could be detected earlier before symptoms show up, when prevention is possible?

At Lucence, we believe that earlier detection is the key to longevity by advancing detection before symptoms even appear. Our ultrasensitive tests deliver insights to guide doctors in providing you with a personalized health action plan.

Everyone’s story is unique. Our wide range of tests aim ensure that there’s a test that fits into everyone’s story. We are here with you at every step of your health journey.

Milestones

2016

Company founded

2017

Raised $9.2M in seed funding
Received Clinical Laboratory License in Singapore

2018

Launched flagship test, LiquidHALLMARK®

2019

Raised $20M Series A Led by IHH healthcare
Singapore Laboratory received federal CLIA license, California out-of-state license and CAP accreditation

2020

Palo Alto Lab received California state license and federal CLIA license

2021

Palo Alto Lab received CAP accreditation
Launched multicenter prospective study in US and Singapore

2022

Expanded US LiquidHALLMARK® profiling to include both ctDNA and ctRNA

2023

US Medicare coverage achieved for LiquidHALLMARK®

2025

Strategic collaboration with Mayo Clinic Laboratories to increase LiquidHALLMARK® access in US
Launched LucenceINSIGHT® MCED test with ctRNA tumor marker boost and CardioHemeRisk™ clonal hematopoiesis test